Session

Overview: Although there have been significant advancements in systemic therapy of recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC), the prognosis for patients remains unfavorable. Antibody-drug conjugates have revolutionized treatment in multiple cancers, both alone and in combination with immunotherapy. Apoptosis-targeting agents have shown promising initial results in the locally advanced setting combined with chemoradiotherapy. Immunotherapy has been shown to extend survival in R/M HNSCC. As a result, novel immunotherapy strategies are presently undergoing clinical evaluation to increase cure rates for head and neck cancer. This session will explore the recent progress in systemic treatment for patients with head and neck cancer.